S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
NASDAQ:IBRX

ImmunityBio Stock Forecast, Price & News

$5.17
+0.12 (+2.38%)
(As of 01/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.81
$5.19
50-Day Range
$5.05
$7.79
52-Week Range
$4.81
$45.42
Volume
2.68 million shs
Average Volume
1.82 million shs
Market Capitalization
$2.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.99
30 days | 90 days | 365 days | Advanced Chart
Receive IBRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter.


About ImmunityBio

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Headlines

ImmunityBio (NASDAQ:IBRX) Sets New 12-Month Low at $5.07
January 24, 2022 |  americanbankingnews.com
ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $6.19
January 19, 2022 |  americanbankingnews.com
Form 8-K ImmunityBio, Inc. For: Jan 07 - StreetInsider.com
January 12, 2022 |  streetinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IBRX
Fax
N/A
Employees
171
Year Founded
N/A

Sales & Book Value

Annual Sales
$110 thousand
Price / Sales
18,686.97
Book Value
$1.08 per share

Profitability

Net Income
$-92.38 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
80,593,000
Market Cap
$2.06 billion
Optionable
Optionable

Company Calendar

Today
1/28/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.48 out of 5 stars

Medical Sector

1101st out of 1,417 stocks

Biological Products, Except Diagnostic Industry

174th out of 207 stocks

Analyst Opinion: 3.5Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












ImmunityBio (NASDAQ:IBRX) Frequently Asked Questions

Is ImmunityBio a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunityBio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ImmunityBio stock.
View analyst ratings for ImmunityBio
or view top-rated stocks.

Are investors shorting ImmunityBio?

ImmunityBio saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 12,310,000 shares, an increase of 18.0% from the December 15th total of 10,430,000 shares. Based on an average trading volume of 1,490,000 shares, the days-to-cover ratio is presently 8.3 days. Approximately 15.3% of the company's stock are short sold.
View ImmunityBio's Short Interest
.

What price target have analysts set for IBRX?

1 analysts have issued 12-month price targets for ImmunityBio's shares. Their forecasts range from $25.00 to $25.00. On average, they expect ImmunityBio's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 383.6% from the stock's current price.
View analysts' price targets for ImmunityBio
or view top-rated stocks among Wall Street analysts.

Who are ImmunityBio's key executives?

ImmunityBio's management team includes the following people:

What is ImmunityBio's stock symbol?

ImmunityBio trades on the NASDAQ under the ticker symbol "IBRX."

Who are ImmunityBio's major shareholders?

ImmunityBio's stock is owned by many different institutional and retail investors. Top institutional investors include Sheets Smith Wealth Management (0.04%), Clearwater Capital Advisors LLC (0.04%), Allspring Global Investments Holdings LLC (0.03%), Russell Investments Group Ltd. (0.03%) and Liberty One Investment Management LLC (0.01%). Company insiders that own ImmunityBio stock include Barry J Simon, Cheryl Cohen and Richard Adcock.
View institutional ownership trends for ImmunityBio
.

Which major investors are selling ImmunityBio stock?

IBRX stock was sold by a variety of institutional investors in the last quarter, including Clearwater Capital Advisors LLC. Company insiders that have sold ImmunityBio company stock in the last year include Barry J Simon, and Cheryl Cohen.
View insider buying and selling activity for ImmunityBio
or view top insider-selling stocks.

Which major investors are buying ImmunityBio stock?

IBRX stock was acquired by a variety of institutional investors in the last quarter, including Allspring Global Investments Holdings LLC, Liberty One Investment Management LLC, Russell Investments Group Ltd., and Sheets Smith Wealth Management.
View insider buying and selling activity for ImmunityBio
or or view top insider-buying stocks.

How do I buy shares of ImmunityBio?

Shares of IBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunityBio's stock price today?

One share of IBRX stock can currently be purchased for approximately $5.17.

How much money does ImmunityBio make?

ImmunityBio has a market capitalization of $2.06 billion and generates $110 thousand in revenue each year.

How many employees does ImmunityBio have?

ImmunityBio employs 171 workers across the globe.

What is ImmunityBio's official website?

The official website for ImmunityBio is immunitybio.com.

Where are ImmunityBio's headquarters?

ImmunityBio is headquartered at 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121.

How can I contact ImmunityBio?

ImmunityBio's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The company can be reached via phone at (844) 696-5235 or via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.